Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 130
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00216125 | Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer | ||
| NCT02500121 | Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer | ||
| NCT04690855 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer | ||
| NCT03396471 | Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary | ||
| NCT05406713 | Pembrolizumab in Muscle-invasive Bladder Cancer | ||
| NCT00235235 | A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer | ||
| NCT01736917 | Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors | ||
| NCT06809140 | Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer | ||
| NCT03476174 | Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma | ||
| NCT03099564 | Pembrolizumab Plus Y90 Radioembolization in HCC Subjects | ||
| NCT01215136 | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | ||
| NCT03783936 | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | ||
| NCT07218666 | Zanzalintinib in Men With Aggressive Variant Prostate Cancer | ||
| NCT00216060 | Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy | ||
| NCT02101385 | Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer | ||
| NCT00216151 | Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma | ||
| NCT06503614 | A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer | ||
| NCT01034631 | BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma | ||
| NCT01177683 | Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma | ||
| NCT00319735 | Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas | ||
| NCT03241186 | Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | ||
| NCT00859339 | Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC | ||
| NCT03960151 | Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy | ||
| NCT03317158 | Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder | ||
| NCT02549209 | Pembro/Carbo/Taxol in Endometrial Cancer | ||
| NCT06493019 | Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer | ||
| NCT00706641 | Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder | ||
| NCT03400254 | Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER") | ||
| NCT01186458 | Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | ||
| NCT02586610 | Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer | ||
| NCT02581215 | Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer | ||
| NCT02581059 | Efficacy of Ginseng for Patients on Regorafenib | ||
| NCT01071928 | Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma | ||
| NCT00216073 | Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer | ||
| NCT02375672 | Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer | ||
| NCT05442216 | Tagraxofusp and Azaxitadine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents | ||
| NCT00890955 | Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies | ||
| NCT04541173 | Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) | ||
| NCT04711824 | Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases | ||
| NCT03913455 | Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer | ||
| NCT04289779 | Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer | ||
| NCT02982720 | Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron | ||
| NCT03552380 | Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma | ||
| NCT00732303 | Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer | ||
| NCT00216086 | Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer | ||
| NCT04610684 | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases | ||
| NCT00317200 | A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer | ||
| NCT00234494 | Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer | ||
| NCT02365766 | Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects | ||
| NCT01485874 | Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer |
